Articles from Bluejay Diagnostics

Completes SYMON-II clinical study enrollment and advances clinical validation activities.Achieves critical manufacturing milestone ahead of contractual deadline, strengthening supply chain and commercialization readiness.Targets FDA 510(k) submission in the first half of 2027.

ACTON, MA / ACCESS Newswire / October 30, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-4 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 3, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 3, 2026 under the Company's existing trading symbol, "BJDX." At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633707.

Company Achieves Toray Contractual Milestone with Establishment of Manufacturing Site

SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory Submission